Latest Breaking News On - அலிஸ்டர் கோர்டந் - Page 1 : comparemela.com
Tram drivers slam Metrolink bosses over out of control thugs on the line
manchestereveningnews.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from manchestereveningnews.co.uk Daily Mail and Mail on Sunday newspapers.
What to look for in a potential employer and what to avoid
lawyersweekly.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lawyersweekly.com.au Daily Mail and Mail on Sunday newspapers.
Tornagrain: New town continues to take shape with cafe ready to open
pressandjournal.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressandjournal.co.uk Daily Mail and Mail on Sunday newspapers.
Crop Doctor: Rain heightens wheat disease risk at T2 timing >More in
© Tim Scrivener
Wheat growers are being urged to try out new chemistry for their all-important flag leaf fungicide sprays at the end of this month as yield responses from these novel products are more predictable than older actives.
In the second of a two-part series, we ask one independent disease expert and five agronomists across Britain about their strategies for T2 sprays, which are due to be applied towards the end of May.
Many wheat growers have reduced or cut out earlier T0 and T1 fungicide sprays altogether due to dry weather limiting disease, but the T2 flag leaf application has the biggest beneficial yield effect.
Daiichi Sankyo UK, Limited: ENHERTU - (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
Reimbursement decisions in Scotland, Wales, and Northern Ireland to be announced later this year
Daiichi Sankyo UK, Limited
(hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies.
In the UK, almost 54,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive.